golotimod

Golotimod is an orally bioavailable synthetic dipeptide composed of D-glutamine and L-tryptophan linked by a gamma-glutamyl bond. It acts as an immunomodulator, primarily by stimulating the T-helper 1 (Th1) immune response and modulating the Toll-like receptor (TLR) pathway. Golotimod enhances T-cell differentiation, macrophage activation, and increases production of cytokines such as interleukin 2 (IL-2) and interferon-gamma (IFN-gamma). It also inhibits STAT3-mediated signaling, which may reverse immunosuppression and stimulate anti-tumor immune responses. The drug has demonstrated potential in treating tuberculosis—where it improved mycobacterial clearance, cavity healing, immune parameters, and symptoms—as well as various viral and bacterial infections. Clinical trials have explored its use for tuberculosis, hepatitis C, mucositis/stomatitis, head and neck neoplasms, asthma, herpesviridae infections including HSV2 genital herpes recurrence[1][2][3][4][5][6][7].

Brand names

golotimod

Other names

golotimodGamma-D-glutamyl-L-tryptophan